L-Carnosine
PreclinicalSmall molecule
L-Carnosine is one of 14 small molecule programs targeting Bipolar I Disorder. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Bipolar I Disorder
#DrugCompanyPhaseTrials
1Zyprexa
MMODAG GmbH
Approved
Risperdal
WWim Janssens
Approved
Lexapro
AbbVieApproved
Lithobid
SSolvay Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
OLZ/SAM
AAlkermes, Inc.
Phase 3
Endoxifen
JJina Pharmaceuticals Inc.
Phase 3
Icalcaprant
AbbViePhase 2
NBI-1117568
Neurocrine BiosciencesPhase 2
Treatment as Usual
AAB Biotics, SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Peripheral Neuropathy1 trial
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
Completed·—·Phase 1/2·NCT02808624·65 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-Carnosine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Pittsburgh